3,546 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by Marble Wealth LLC

Marble Wealth LLC bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the fourth quarter, Holdings Channel reports. The institutional investor bought 3,546 shares of the medical research company’s stock, valued at approximately $2,055,000.

A number of other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Thermo Fisher Scientific by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company’s stock worth $19,778,774,000 after purchasing an additional 288,296 shares in the last quarter. Capital World Investors increased its position in shares of Thermo Fisher Scientific by 7.4% during the 3rd quarter. Capital World Investors now owns 10,285,145 shares of the medical research company’s stock worth $4,988,132,000 after purchasing an additional 706,572 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Thermo Fisher Scientific by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 8,196,477 shares of the medical research company’s stock worth $4,728,129,000 after purchasing an additional 26,425 shares in the last quarter. Franklin Resources Inc. increased its position in Thermo Fisher Scientific by 21.0% in the 3rd quarter. Franklin Resources Inc. now owns 5,925,671 shares of the medical research company’s stock valued at $2,874,069,000 after acquiring an additional 1,028,125 shares in the last quarter. Finally, Norges Bank acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at about $3,072,744,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

TMO has been the subject of several research reports. Wells Fargo & Company lowered their price objective on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Wednesday, April 8th. KeyCorp restated an “overweight” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. Wall Street Zen cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Morgan Stanley restated an “overweight” rating and issued a $620.00 price objective on shares of Thermo Fisher Scientific in a research report on Monday, April 27th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Buy” and an average target price of $612.24.

Thermo Fisher Scientific Stock Down 2.7%

Shares of NYSE:TMO opened at $480.62 on Wednesday. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $643.99. The company has a 50 day moving average of $480.40 and a 200-day moving average of $533.68. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. The stock has a market cap of $178.61 billion, a price-to-earnings ratio of 26.42, a P/E/G ratio of 2.19 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company had revenue of $11.01 billion during the quarter, compared to analysts’ expectations of $10.86 billion. During the same quarter in the previous year, the company earned $5.15 EPS. Thermo Fisher Scientific’s revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be given a dividend of $0.47 per share. The ex-dividend date is Monday, June 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific’s payout ratio is currently 10.34%.

Insider Transactions at Thermo Fisher Scientific

In related news, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the transaction, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. The trade was a 1.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.